Immunotherapy with an alum-adsorbed Parietaria-pollen allergoid: A 2-year, double-blind, placebo-controlled study

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 52, Issue 1, 1997, Pages 65-74

  Tari, M G ^a   Mancino, M ^a   Ghezzi, E ^b   Frank, E ^c   Cromwell, O ^c  

^a Department of Internal Medicine   (Italy)

^b Bracco SpA   (Italy)

^c ALLERGOPHARMA JOACHIM GANZER KG   (Germany)

Author keywords

allergic rhinitis; allergoid; desensitization; immunologic; immunotherapy; Parietari a pollen

Indexed keywords

ALLERGEN; ALLERGOVIT; IMMUNOGLOBULIN E; POLLEN ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ALLERGIC RHINITIS; ANTIBODY RESPONSE; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; SKIN TEST;

EID: 0030968486     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1997.tb02547.x     Document Type: Article

References (29)

1. Maasch HJ, Marsh DG. Standardized extracts: modified allergens - allergoids. Clin Rev Allergy 1987;5:89-106.
2. Bousquet J, Hejjaoui A, Skassa-Brociek W, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol 1987;80:591-8.
3. Bousquet J, Hejjaoui A, Soussana M, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy. J Allergy Clin Immunol 1990;85:490-7.
4. Bousquet J, Maasch HJ, Hejjaoui A, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhino-conjunctivitis and asthma. J Allergy Clin Immunol 1989; 84:546-56.
5. Bousquet J, Maasch H, Martinot B, Hejjaoui A, Wahl R, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol 1988;82:439-46.
6. Pastorello EA, Pravettoni V, Incorvaia C, et al. Clinical and immunological effects of immunotherapy with alumadsorbed grass allergoid in grass-pollen-induced hay fever. Allergy 1992;47:281-90.
7. Marsh DG, Norman PS, Roebber M, Lichtenstein LM. Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. J Allergy Clin Immunol 1981;68:449-59.
8. Salgado J, Campama M, Gilabert A, Queralt J. Biological characterization of a formylated allergoid from Dermatophagoides pteronyssinus. Rev Esp Fisiol 1992;48:245-51.
9. Norman PS, Lichtenstein LM, Kagey-Sobotka A, Marsh DG. Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J Allergy Clin Immunol 1982;70: 248-60.
10. D'Amato G, Ruffilli A, Sacerdoti G, Bonini S. Parietaria pollinosis: a review. Allergy 1992;47:443-9.
11. Basomba A. The importance of allergen dosage and treatment schedules in immunotherapy. Proceedings XII International Congress of Allergology and Clinical Immunology, Washington, 1985:335-40.
12. D'Amato G, Ruffilli A, Ortolani C. Allergenic significance of Parietaria (pellitory-of-the-wall) pollen. In: D'Amato G, Spieksma FTM, Bonini S. editors. Allergenic pollen and pollinosis in Europe. Oxford: Blackwell Scientific, 1991: 113-18.
13. Bruno G, Mari A, Frank E, Franceschini P, Biocca MM, Balsano F. Untersuchungen mit Parietaria-Allergoiden in der Immuntherapie. I. Sicherheit und Wirksamkeit der Immuntherapie mit aluminiumadsorbierten Allergenund Allergoid-Extrakten aus Parietaria-judaica-Pollen. Allergologie 1990;13:380-6.
14. Bruno G, Mari A, Frank E, Franceschini P, Biocca MM, Balsano F. Untersuchungen mit Parietaria-Allergoidern in der Immuntherapie. II. Immunologische Veränderungen während der Immuntherapie mit aluminiumadsorbierten Allergen- und Allergoid-Extrakten aus Parietaria-judaica-Pollen. Allergologie 1990;13:424-32.
15. Matsumoto K, Okubo K, Yokoyama MM. Distribution of marker specific lymphocyte in healthy human subjects. J Clin Lab Immunol 1985;16:143-7.
16. Hauser U, Bachert C, Frank E. Hemmung des Einstroms von Entzündungszellen in die Nasenschleimhaut durch die allergen-spezifische Immuntherapie. Allergo J 1995;4:164-8.
17. Hauser U, Cromwell O, Frank E, Bachert C. Reduction of the cytokine content of nasal secretions as a result of allergen specific-immunotherapy. Allergy 1995;50 Suppl 26: 276-7.
18. Fling JA, Ruff ME, Parker WA, et al. Suppression of the late cutaneous response by immunotherapy. J Allergy Clin Immunol 1989;83:101-9.
19. Rocklin RE. Immune mechanisms in allergen specific immunotherapy. Clin Immunol Immunopathol 1989;53:S119-31.
20. Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine messenger RNA expression during allergen-induced latephase cutaneous responses. J Clin Invest 1993;92:644-51.
21. Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978;2:912-15.
22. Durham SR, Varney VA, Jacobson MR, Sudderick RM, Kay AB. Effect of grass pollen immunotherapy on allergen-induced early and late nasal responses [Abstract]. J Allergy Clin Immunol 1993;91:290.
23. van Metre TE, Adkinson NF. Immunotherapy for aeroallergen disease. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW, editors. Allergy: principles and practice. 4th ed. 1993:1489-1509.
24. εRI) mediates IgE-dependent allergen presentation. J Immunol 1995;154:6285-90.
25. Mudde G, Bheekha R, Bruijnzeel-Koomen CAFM. Consequences of IgE/CD23-mediated antigen presentation in allergy. Immunol Today 1995;16:380-3.
26. Fiebig H. Immunologische Aspekte der spezifischen Immuntherapie (Hyposensibilisierung). I. Die Steuerung der IgE-Synthese. Allergo J 1995;4:336-9.
27. Fiebig H. Immunologische Aspekte der spezifischen Immuntherapie (Hyposensibilisierung). II. Die Umorientierung der T-Helferzellreaktion. Allergo J 1995;4:377-82.
28. Nagaya H. Induction of antigen-specific suppressor cells in patients with hay fever receiving immunotherapy. J Allergy Clin Immunol 1985;75:388-94.
29. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double blind study. Allergol Immunopathol (Madr) 1990;18:277-84.